bladder cancer

ESMO: AstraZeneca's Imfinzi extends life in bladder cancer type. Will FDA push back on its perioperative trial design?
Fierce Pharma
Sun, 09/15/24 - 06:22 pm
ESMO
AstraZeneca
Imfinzi
bladder cancer
Fresh off first regulatory win, ImmunityBio hints at financial troubles
First Word Pharma
Fri, 09/6/24 - 11:13 am
ImmunityBio
layoffs
anktiva
bladder cancer
Gilead’s Trodelvy stumbles in late-stage trials but remains prized cancer asset
BioSpace
Mon, 07/1/24 - 11:39 am
Gilead Sciences
Trodelvy
bladder cancer
lung cancer
clinical trials
enGene drops preclinical cystic fibrosis program to strengthen bladder cancer strategy
Fierce Biotech
Fri, 06/14/24 - 11:13 am
enGene
bladder cancer
cystic fibrosis
Gilead’s Trodelvy suffers double whammy as failed bladder cancer trial raises flag over early deaths
Fierce Pharma
Thu, 05/30/24 - 11:17 pm
Gilead Sciences
clinical trials
Trodelvy
bladder cancer
J&J’s ‘Pretzel’ Drug-Device Combo Scores in Mid-Stage Bladder Cancer Study
BioSpace
Mon, 05/6/24 - 05:52 pm
JNJ
clinical trials
TAR-200
drug-device combos
bladder cancer
As rival Merck monopolizes BCG supply, ImmunityBio taps Serum Institute for new combo's manufacturing
Fierce Pharma
Mon, 05/6/24 - 11:30 am
Merck
ImmunityBio
BCG
vaccines
bladder cancer
CG follows big IPO with new results for bladder cancer drug
BioPharma Dive
Sun, 05/5/24 - 11:35 pm
CG Oncology
IPOs
bladder cancer
cretostimogene
Padcev, Keytruda, and Balversa leave little room for Opdivo in urothelial carcinoma
Clinical Trials Arena
Thu, 03/21/24 - 06:41 pm
bladder cancer
urothelial cancer
Merck
Pfizer
Bristol Myers Squibb
Padcev
Keytruda
Balversa
Opdivo
Bristol Myers, overshadowed by ADC rival, wins FDA nod for Opdivo combo in bladder cancer
Fierce Pharma
Fri, 03/8/24 - 11:54 am
Bristol Myers Squibb
Opdivo
FDA
bladder cancer
6 first-half 2024 oncology data readouts to watch
BioSpace
Mon, 02/26/24 - 11:20 am
oncology
clinical trials
Daiichi Sankyo
AstraZeneca
Enhertu
metastatic breast cancer
Gilead Sciences
Trodelvy
bladder cancer
GSK
Zejula
Jemperli
ovarian cancer
Roche
tiragolumab
Tecentriq
non-small cell lung cancer
Cue Biopharma
CUE-101
head and neck cancer
Elicio Therapeutics
ELI-002
solid tumors
Ferring’s microbiome and gene therapy firsts take the company beyond reproductive health
Pharma Voice
Thu, 02/22/24 - 11:45 am
Ferring Pharmaceuticals
gene therapy
microbiome
bladder cancer
C. difficile
After Padcev combo’s major triumph, Merck’s Keytruda delivers partial win in bladder cancer
Fierce Pharma
Fri, 01/26/24 - 12:03 pm
Merck
Keytruda
bladder cancer
Johnson & Johnson wins full FDA approval for bladder cancer therapy Balversa
Seeking Alpha
Sun, 01/21/24 - 05:11 pm
JNJ
bladder cancer
Balversa
erdafitinib
urothelial cancer
CG Oncology aims for $209M IPO, as more biotechs eye path to public markets
Fierce Biotech
Thu, 01/18/24 - 11:11 am
CG Oncology
IPOs
oncology
bladder cancer
CG Oncology plans IPO plunge ahead of phase 3 bladder cancer drug readout
Fierce Biotech
Wed, 01/3/24 - 09:35 am
CG Oncology
IPOs
bladder cancer
Merck, Astellas and Pfizer bring down the house with Keytruda-Padcev FDA nod in bladder cancer
Fierce Pharma
Tue, 12/19/23 - 10:26 am
Merck
Astellas
Pfizer
Keytruda
Padcev
bladder cancer
BMS chases Merck/Seagen with first-line bladder cancer filing
Pharmaphorum
Tue, 12/5/23 - 11:53 pm
Bristol Myers Squibb
Opdivo
bladder cancer
urothelial cancer
Merck
Seagen
FDA starts review of Padcev/Keytruda for bladder cancer
Pharmaphorum
Fri, 12/1/23 - 09:35 am
Merck
Astellas
Seagen
Padcev
bladder cancer
FDA
priority review
Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO
BioSpace
Mon, 10/23/23 - 05:15 pm
ESMO
Merck
Bristol Myers Squibb
bladder cancer
PD-1 inhibitors
Keytruda
Padcev
Opdivo

Pages